Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 345 participants.

Also called NCT02988115

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 345 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02988115
Other papers using this trial's data
  • Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance Journal of the American Heart Association, 2019-04-02 DOI, PubMed 30922146, PMC6509724 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02988115. Randomized; triple masking; primary purpose treatment. Start 2016-11-16 (actual); primary completion 2018-03-16 (actual). Results posted on 2020-04-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant
Acronym
CLEAR Serenity
Condition
Hypercholesterolemia
Condition
Atherosclerotic Cardiovascular Disease
Condition
Statin Adverse Reaction
Intervention (Drug)
bempedoic acid
Intervention (Other)
placebo
Lead sponsor
Esperion Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02988115
Content hash
b9c09a686c35728347256f62502993edb6d1ff2a2732ccd7d34db6b58d674f85